$STE

Sohi Mohsen sold $957K of STE

Sohi Mohsen sold 4,058 shares of STERIS plc (STE) at $235.78 ($0.96M total) on 2026-08-12.

Original reporting
SEC EDGAR · Sohi Mohsen
Published Aug 12, 2026, 8:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$STE
Neutral
medium confidence
Mentioned
$STE
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STENeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price, and post-transaction holdings by a director on 2026-08-12.

02

Market read

A director’s open-market sale is disclosed, but there is no accompanying operational, financial, or regulatory catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without additional context, trading impact is usually limited.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-12 (same day as transaction)

Background

The article is an SEC Form 4 insider transaction disclosure for STERIS plc.

Company-level read

Ticker impact

$STENeutralMedium confidence
Context

STERIS director Sohi Mohsen filed a Form 4 selling 4,058 shares at $235.7800 on 2026-08-12 for about $956,795.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The filing is primary-source and time-stamped, but the article provides no accompanying company news, guidance, or transaction context beyond the sale details.

Market effects

No sector read-through is provided beyond a single insider sale.

None indicated.

None indicated.

Counterpoint

Absence of a disclosed 10b5-1 plan could be interpreted as less mechanical selling, but the article still lacks any linkage to company fundamentals.

Key entities

  • STERIS plc

    Subject of the Form 4 insider transaction disclosure.

  • Sohi Mohsen

    Director who sold 4,058 shares on 2026-08-12.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Notable healthcare headlines for the week: J&J, UnitedHealth, and CVS in focus

UnitedHealth (UNH) raised 2026 earnings guidance after Q3 results beat estimates, with adjusted EPS at $4.69. Johnson & Johnson (JNJ) also raised full-year guidance. Roche (RHHBY) signed a $1.16B deal for an obesity drug. STERIS (STE) to acquire Xodus Medical for $2.1B. Iambic Therapeutics (IAM) debuted with a 10% rise. CVS (CVS) agreed to pay $315M over opioid prescription allegations.

$STEHighAI 9/10

Steris Announces Major Acquisition of Xodus Medical, Inc.

STERIS (STE) agreed to acquire Xodus Medical, Inc. for $2.1B in cash, with up to $150M in earnout payments, subject to regulatory approval. The deal is expected to close by December 31, 2026, and will be financed primarily with debt. Analysts rate STE stock as Buy with a $269 price target, citing strong financial quality and growth guidance.

$STEHighAI 9/10

Steris inks $2.1B Xodus buyout to expand consumables portfolio

Steris (STE) agreed to acquire Xodus Medical for $2.1B, expecting $245M in annual sales. The deal expands Steris' healthcare consumables portfolio, with debt financing and potential performance-based payouts. Analysts expect earnings per share growth from 2027. Steris aims to close the deal this year, following its M&A strategy focused on hospital-related technology.

$STEHighAI 9/10

Steris outlays $2.1bn to acquire Xodus Medical

Steris (STE) agreed to acquire Xodus Medical, a privately held surgical safety solutions developer, for $2.1 billion. The deal will expand Steris's healthcare consumables portfolio, including Xodus's surgical products like the Pink Pad. Steris expects the acquisition to complement its offerings and drive growth, with Xodus projecting $245 million in 2026 revenue. Steris's healthcare consumables segment grew 10% year-on-year in Q2 2026.